Pharmalittle Updates: Novo Holdings and Catalent, Sanofi Under Scrutiny
Monday, 16 December 2024, 06:27
Novo Holdings Acquisition of Catalent
Pharmalittle reveals that Novo Holdings can proceed with its $16.5 billion acquisition of Catalent after U.S. regulators declined to challenge the deal. This acquisition marks a significant milestone for Novo Holdings.
Sanofi Sanction Threats
In other news, Sanofi faces potential sanctions from regulatory bodies that could impact its operations. This situation highlights the heightened scrutiny in the pharmaceutical industry.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.